A convergent synthetic platform for anticancer drugs formulation with nanoparticle delivery for the treatment and nursing care of glioma cancer. (December 2021)

• Record Type: Journal Article
• Authors: Wang, Xiaoying; Dong, Haiqing
• Is Part Of: Process biochemistry. Volume 111:Part 2(2021)
• Page Start: 172
• Page End: 180
• Publication Date: 2021-12
• Subjects: Combinational delivery -- Glioma cancer -- Apoptosis -- In vivo antitumor efficacy; Biochemical engineering -- Periodicals; Biotechnology -- Periodicals; Biochemistry -- periodicals; Biotechnology -- periodicals; Chemical Engineering -- periodicals; Génie biochimique -- Périodiques; Biotechnologie -- Périodiques; Biochemical engineering; Biotechnology; Periodicals; 660.63
• DOI: 10.1016/j.procbio.2021.10.020
• Languages: English
• ISSNs: 1359-5113

Abstract

Graphical abstract: Highlights: We have established a new method dual drug delivery of model exhibits a great anticancer potential. PTX@SN38-NMS induced significant cell death in human glioma cells in vitro. The apoptosis was confirmed by the dual staining method and flow cytometry analysis. The in vivo antitumor efficacy results show the substantial inhibition of tumour development. Abstract: The cytotoxicity of targeted combinational chemotherapy is significantly more significant than that of other approaches. This study aimed to develop compostable poly(caprolactone)-poly(ethylene glycol)-poly(-caprolactone) (PCECs) nanomaterials (NMs) for the delivery of irinotecan (SN38) and paclitaxel (PTX) to examine the anticancer effect of (PTX@SN38-NMs) against glioma carcinoma cells in vivo and in vitro. The fabricated PTX@SN38-NMs were 27.97 ± 1.87 nm in size and had a less polydispersity index (0.156 ± 0.030). Further, PTX@SN38-NMs showed dose-dependent cytotoxic effects in LN229 cells, with a higher range of apoptosis than free drugs. To assess the in vivo antitumor activity, PTX@SN38-NMs were administered intravenously injected to xenografted with LN229 cells. Substantial inhibition of tumour development was observed with extended survival time and decreased side effects with PTX@SN38-NMs compared to free drugs (PTX + SN38), indicating the chemotherapeutic efficiency of the drug delivery system. Overall, this examination established that the drug delivery framework of PTX@SN38-NMs could be utilized to effectively glioma carcinoma cells in the future treatment and care.